Breaking News, Collaborations & Alliances

Ardelyx, Kyowa Hakko Kirin Partner for Cardiorenal Diseases

Ardelyx will receive a $30M upfront payment and subsequent milestones for Tenapanor

Ardelyx and Kyowa Hakko Kirin have entered into a license agreement that gives Kyowa Hakko Kirin exclusive rights to develop and commercialize Ardelyx’s lead investigational product, tenapanor, for the treatment of cardiorenal diseases in Japan.    Tenapanor is an oral, minimally systemic NHE3 inhibitor that is in Phase 3 development in the United States for the treatment of hyperphosphatemia in patients with end-stage renal disease who are on dialysis.   Under the terms of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters